arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Calidi Biotherapeutics, Inc.

CLDI

$1.61 ▼ -0.17 (-9.27%) at close

6 Visible periods

25 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Fair

Bullish

auto_awesome

Analytical Summary

Calidi Biotherapeutics, Inc. shows strong fundamentals with top-quartile Debt to Equity. The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap —

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -464.7% ↗

FCF / Share None

Trailing P/E —

Price / Book 3.1x

FCF Yield —

Debt / Equity 0.16

info Valuation on last close. End-of-day price, Aug 7, 2026.

6-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-19.91M

↑ +10.1% —

FCF / Share Free cash flow per share

$-2.46

↑ +84.6% —

Long-Term Debt Long-term obligations

$600.00K

— 0.0% —

trending_up

Bullish Indicators

Debt to EquityDebt to Equity is in the top quartile (lower is better)

warning

Bearish Risks

No bearish risks detected.

Health Breakdown

Financial Health ↓

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Mar 23, 2021 10-K ↗
EPS Growth YoY (%)	-100.3% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	82.9% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	N/M	—	—	—
Net Income Growth YoY (%)	10.1% Fair ↑ Fair Improving Year-over-year change in net income	24.2% Good Good Year-over-year change in net income	-14.9% Weak Weak Year-over-year change in net income	—	—	—
FCF Growth YoY (%)	—	84.6% Excellent Excellent Year-over-year change in free cash flow	-930.1% Weak Weak Year-over-year change in free cash flow	—	—	—

💰 Are margins durable? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Mar 23, 2021 10-K ↗
Effective Tax Rate (%) (%)	-0.1% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.1% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.1% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—
FCF / Net Income (x)	1.07x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.89x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.92x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.52x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Mar 23, 2021 10-K ↗
Return on Invested Capital (%)	-464.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-1021.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	469.8% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	45.9% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—	—
Return on Capital (%) (%)	-228.5% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-153.5% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-289.4% Weak Weak Operating profit relative to total assets Optimal: > 10%	-890.6% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—
Return on Common Equity (%) (%)	—	—	—	50.4% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+236%)	—	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Mar 23, 2021 10-K ↗
Debt to Equity (x)	0.16x Excellent ↑ Excellent Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-73%)	0.39x Good Good Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-35%)	-0.25x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-142%)	—	—	—
Interest Coverage (x)	-202.40x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-31.11x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-26.36x Weak Weak Operating income divided by interest expense Optimal: > 5x	-115.64x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—
Net Debt (USD)	$600.00K	$-9.00M	$2.06M	—	$-1.06M	—
Debt / EBITDA (x)	-0.03x Excellent ↑ Excellent Improving Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.03x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.07x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Mar 23, 2021 10-K ↗
Revenue per Share (USD)	—	—	—	$0.01	—	—
Basic EPS, GAAP (USD)	$-5.95	$-2.97	$-17.33	$2.99	—	—
Free Cash Flow per Share (USD)	—	$-2.46	$-16.00	$-1.55	—	—
Book Value per Share (USD)	$0.52	$0.07	$-2.32	$-5.88	$-0.64	—
Tangible Book Value per Share (USD)	$0.52	$0.07	$-2.32	$-5.88	$-0.64	—
Basic Weighted Avg Shares (shares)	4,302	8.01M	1.69M	8.51M	—	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Mar 23, 2021 10-K ↗
Working Capital (USD)	$2.32M	$731.00K	$-5.93M	$-42.20M	$1.07M	—
LT Debt (USD)	$600.00K	$600.00K	$2.06M	—	—	—
Total Equity (USD)	$3.76M	$1.53M	$-8.23M	$-50.44M	$-14.69M	$0.00

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Mar 23, 2021 10-K ↗
Sales/Revenue/Turnover (USD)	—	—	—	$45.00K	—	—
Depreciation Expense (USD)	—	$402.00K	$392.00K	$260.00K	—	—
Net Income, GAAP (USD)	$-19.91M	$-22.14M	$-29.22M	$-25.43M	—	—
Operating Cash Flow (USD)	$-21.29M	$-19.69M	$-26.98M	$-13.21M	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 6 years · 22 quarters

Calidi Biotherapeutics, Inc.

Analytical Summary

6-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare CLDI with peers